319 related articles for article (PubMed ID: 31952272)
1. Androgen Receptor in Breast Cancer-Clinical and Preclinical Research Insights.
Anestis A; Zoi I; Papavassiliou AG; Karamouzis MV
Molecules; 2020 Jan; 25(2):. PubMed ID: 31952272
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor: Structure, signaling, function and potential drug discovery biomarker in different breast cancer subtypes.
Shukla N; Shah K; Rathore D; Soni K; Shah J; Vora H; Dave H
Life Sci; 2024 Jul; 348():122697. PubMed ID: 38710280
[TBL] [Abstract][Full Text] [Related]
3. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review.
Kono M; Fujii T; Lim B; Karuturi MS; Tripathy D; Ueno NT
JAMA Oncol; 2017 Sep; 3(9):1266-1273. PubMed ID: 28301631
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor expression in breast cancer: Implications on prognosis and treatment, a brief review.
Jahan N; Jones C; Rahman RL
Mol Cell Endocrinol; 2021 Jul; 531():111324. PubMed ID: 34000352
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer.
Salvi S; Bonafè M; Bravaccini S
Semin Cancer Biol; 2020 Feb; 60():132-137. PubMed ID: 31002873
[TBL] [Abstract][Full Text] [Related]
6. The Role of the Androgen Receptor Signaling in Breast Malignancies.
Christopoulos PF; Vlachogiannis NI; Vogkou CT; Koutsilieris M
Anticancer Res; 2017 Dec; 37(12):6533-6540. PubMed ID: 29187427
[TBL] [Abstract][Full Text] [Related]
7. Consideration of breast cancer subtype in targeting the androgen receptor.
Venema CM; Bense RD; Steenbruggen TG; Nienhuis HH; Qiu SQ; van Kruchten M; Brown M; Tamimi RM; Hospers GAP; Schröder CP; Fehrmann RSN; de Vries EGE
Pharmacol Ther; 2019 Aug; 200():135-147. PubMed ID: 31077689
[TBL] [Abstract][Full Text] [Related]
8. Androgen Receptor in Breast Cancer: From Bench to Bedside.
Chen M; Yang Y; Xu K; Li L; Huang J; Qiu F
Front Endocrinol (Lausanne); 2020; 11():573. PubMed ID: 32982970
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor signaling pathways as a target for breast cancer treatment.
Pietri E; Conteduca V; Andreis D; Massa I; Melegari E; Sarti S; Cecconetto L; Schirone A; Bravaccini S; Serra P; Fedeli A; Maltoni R; Amadori D; De Giorgi U; Rocca A
Endocr Relat Cancer; 2016 Oct; 23(10):R485-98. PubMed ID: 27528625
[TBL] [Abstract][Full Text] [Related]
10. Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patients.
Krawczyk N; Neubacher M; Meier-Stiegen F; Neubauer H; Niederacher D; Ruckhäberle E; Mohrmann S; Hoffmann J; Kaleta T; Banys-Paluchowski M; Reinecke P; Esposito I; Janni W; Fehm T
BMC Cancer; 2019 Nov; 19(1):1101. PubMed ID: 31718606
[TBL] [Abstract][Full Text] [Related]
11. The role of the androgen receptor in triple-negative breast cancer.
Shah PD; Gucalp A; Traina TA
Womens Health (Lond); 2013 Jul; 9(4):351-60. PubMed ID: 23826776
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
Gucalp A; Tolaney S; Isakoff SJ; Ingle JN; Liu MC; Carey LA; Blackwell K; Rugo H; Nabell L; Forero A; Stearns V; Doane AS; Danso M; Moynahan ME; Momen LF; Gonzalez JM; Akhtar A; Giri DD; Patil S; Feigin KN; Hudis CA; Traina TA;
Clin Cancer Res; 2013 Oct; 19(19):5505-12. PubMed ID: 23965901
[TBL] [Abstract][Full Text] [Related]
13. Targeting the androgen receptor in triple-negative breast cancer.
Gucalp A; Traina TA
Curr Probl Cancer; 2016; 40(2-4):141-150. PubMed ID: 27816190
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor: A promising therapeutic target in breast cancer.
Vasiliou SK; Diamandis EP
Crit Rev Clin Lab Sci; 2019 May; 56(3):200-223. PubMed ID: 30821186
[TBL] [Abstract][Full Text] [Related]
15. Role of the androgen receptor in triple-negative breast cancer.
Rampurwala M; Wisinski KB; O'Regan R
Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
[TBL] [Abstract][Full Text] [Related]
16. Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer.
Christenson JL; Trepel JB; Ali HY; Lee S; Eisner JR; Baskin-Bey ES; Elias AD; Richer JK
Horm Cancer; 2018 Apr; 9(2):82-94. PubMed ID: 29340907
[TBL] [Abstract][Full Text] [Related]
17. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
[TBL] [Abstract][Full Text] [Related]
18. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.
Naderi A; Chia KM; Liu J
Breast Cancer Res; 2011 Apr; 13(2):R36. PubMed ID: 21457548
[TBL] [Abstract][Full Text] [Related]
19. The Androgen Receptor: Is It a Promising Target?
Gucalp A; Traina TA
Ann Surg Oncol; 2017 Oct; 24(10):2876-2880. PubMed ID: 28766215
[TBL] [Abstract][Full Text] [Related]
20. Triple-negative breast cancer: role of the androgen receptor.
Gucalp A; Traina TA
Cancer J; 2010; 16(1):62-5. PubMed ID: 20164692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
